26/07/2013

MPS IIIA: GENE THERAPY FOR BRAIN AND BODY (SANFILIPPO)

SciBX By Michael J. Haas, Senior Writer

Less than a year after reporting preclinical proof of concept for a systemically
delivered mucopolysaccharidosis IIIA gene therapy, researchers
at the Autonomous University of Barcelona have shown that intracerebral
delivery can substantially improve efficacy in the CNS and treat
symptoms in peripheral organs.1 ESTEVE., who partially funded the
work, is now raising funds to test the approach in the clinic.

To download the full article click the PDF

More information www.esteve.es/en/research-development

You may follow ESTEVE on Twitter via this link: twitter.com/esteve_news.

Last news

  • ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY

    Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spain

    read more
  • NURSES OFFER CARE AND PREVENTION OF DRY EYE, A CONDITION THAT AFFECTS 60% OF PEOPLE OLDER THAN 45 YEARS

    Dry eye care and prevention is a pending issue in the Spanish society and a source of great concern for specific patients, such as those admitted to Intensive Care Units.

    The longer time...

    read more
  • ONE THIRD OF DIABETIC PATIENTS ARE OLDER THAN 75 YEARS AND THEIR HYPOGLYCEMIA GOES UNDETECTED IN 1 OUT OF 5 CASES

    According to experts attending Diabeclass, a meeting organized by ESTEVE
    at its corporate headquarters titled "Managing elderly patients with
    type 2 diabetes".

    The priority ...

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.